|Manufacturer:||Reliant Pharmaceuticals, Inc.|
No interactions have been observed between Axid and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
Axid does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system; therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur.In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
Axid is indicated for up to 8 weeks for the treatment of active duodenal ulcer.
In most patients, the ulcer will heal within 4 weeks.Axid is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s.
after healing of an active duodenal ulcer.
The consequences of continuous therapy with Axid for longer than 1 year are not known.Axid is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.Axid is indicated for up to 8 weeks for the treatment of active benign gastric ulcer.Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.
Axid is contraindicated in patients with known hypersensitivity to the drug.Because cross-sensitivity in this class of compounds has been observed, H2- receptor antagonists, including Axid, should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.